Contaminated losartan sees 3.2m tablets recalled in Taiwan

By Ben Hargreaves

- Last updated on GMT

(Image: Getty/Ake Dynamic)
(Image: Getty/Ake Dynamic)

Related tags Taiwan losartan valsartan

Taiwan’s Food and Drug Administration announced that Siu Guan will instigate a recall of 11 batches of blood pressure tablets.

Siu Guan Chemical Industries – operating out of Chiayi, Taiwan – has instigated a recall of 3.2m tablets of Cosar F.C. 50mg, which are used to control blood pressure.

The company initiated the recall after its own investigation discovered impurities within the medicine.

The losartan used as an active ingredient in the medicine was found to contain N-Nitrosodiethylamine (NDEA), classified as a probable carcinogen​.

According to a statement​ (link in Mandarin) released by the Taiwanese Food and Drug Administration, the company will recall the 11 batches over the course of January.

The agency also stated that it has strengthened its random testing procedure and has introduced requirements for the industry to conduct its own ‘self-inspections’.

Sin Guan was prompted to begin its tests after the discovery of contaminated valsartan products by the European Medicines Agency in July 2018​.

After the initial recall of valsartan produced by Chinese manufacturer, Zhejiang Huahai, the investigation spread further to impact a number of companies​. This led to the examinations of medicines produced using other ‘sartan’ medicines, such as losartan.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us


View more